DEFB109C: A Drug Target / Disease Biomarker (G100286963)

Target Name: DEFB109C

NCBI ID: G100286963

DEFB109C

DEFB109C: A Drug Target / Disease Biomarker

DEFB109C is a drug target (or biomarker) that is being studied for its potential role in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. DEFB109C is a small protein that is expressed in many different tissues throughout the body, including the brain, pancreas, and gastrointestinal tract.

One of the reasons that DEFB109C is being studied as a potential drug target is because it is involved in a number of important biological processes that are important for human health. For example, DEFB109C is involved in the regulation of cell growth and differentiation, which is important for the development and maintenance of tissues and organs. It is also involved in the regulation of inflammation and immune responses, which are important for maintaining the health and integrity of the body.

In addition to its role in important biological processes, DEFB109C is also being studied as a potential drug target because it is thought to be involved in the development and progression of a number of diseases. For example, studies have shown that high levels of DEFB109C are associated with an increased risk of certain cancers, including breast, ovarian, and prostate cancers. Additionally, DEFB109C has also been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

As a result of these studies, DEFB109C has become a focus of interest for researchers who are seeking new treatments for a variety of diseases. If DEFB109C is found to be involved in the development and progression of a particular disease, it could be potential target for a drug that can be developed and administered to treat that disease.

In addition to its potential as a drug target, DEFB109C is also being studied as a potential biomarker. This is because it is thought to be a useful indicator of the presence of certain diseases or conditions. For example, studies have shown that DEFB109C is often reduced in the blood of people with certain cancers, which could make it a potential biomarker for cancer. Additionally, DEFB109C levels have also been shown to be reduced in the urine of people with neurodegenerative diseases, which could make it a potential biomarker for these conditions as well.

Overall, DEFB109C is a protein that is being studied as a potential drug target and biomarker due to its involvement in important biological processes and its association with the development and progression of a number of diseases. Further research is needed to fully understand its potential role in human health.

Protein Name: Defensin Beta 109C

The "DEFB109C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFB109C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets